Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation.

Citation:

Nicolle G, Daher A, Maillé P, Vermey M, Loric S, Bakkar A, Wallerand H, Vordos D, Vacherot F, de Medina SG. Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation. Clin Cancer Res. 2006;12(9):2937-43.